Detalhe da pesquisa
1.
Duvelisib, an oral dual PI3K-δ,γ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study.
Am J Hematol
; 93(11): 1318-1326, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30094870
2.
The pre-clinical absorption, distribution, metabolism and excretion properties of IPI-926, an orally bioavailable antagonist of the hedgehog signal transduction pathway.
Xenobiotica
; 43(10): 875-85, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23527529
3.
The phosphoinositide-3 kinase (PI3K)-δ,γ inhibitor, duvelisib shows preclinical synergy with multiple targeted therapies in hematologic malignancies.
PLoS One
; 13(8): e0200725, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30067771
4.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in hamster aortic atherosclerosis: correlation with in-situ zymography.
Atherosclerosis
; 160(2): 325-37, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11849655
5.
Impact of the Smoothened inhibitor, IPI-926, on smoothened ciliary localization and Hedgehog pathway activity.
PLoS One
; 9(3): e90534, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-24608250
6.
Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors.
Clin Cancer Res
; 19(10): 2766-74, 2013 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-23575478
7.
PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
Chem Biol
; 20(11): 1364-74, 2013 Nov 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-24211136
8.
Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists.
J Med Chem
; 51(21): 6646-9, 2008 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-18842035
9.
IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway.
Nat Immunol
; 4(5): 491-6, 2003 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-12692549